JAK3 and T-cell acute lymphoblastic leukemia: This gain-of-function mutation JAK3 (V722I) replaces valine with isoleucine at position 722 inside the pseudokinase domain leading to constitutive JAK3 activation, as described in megakaryoblastic, prolymphocytic and in T-cell acute lymphoblastic leukemias [5, 7–10].